HDAC11 is overexpressed in certain cancer cell lines, including prostatic (PC-3) (Huo et al., 2020), ovarian (SK-OV-3) (Zhou et al., 2018), and breast cancer (MCF-7) (Gao et al., 2002) cells, and HDAC11 inhibition has shown beneficial effects in neuroblastoma cells (Thole et al., 2017) and Hodgkin lymphoma (Buglio et al., 2011). Here, HDAC11 is linked to cancer.